Kornimate/medical-research-clean huggingface dataset:
a single-center, epidemiological study of the survivorship of the depuy sigma hp unicompartmental knee prosthesis

Conditions: Osteoarthritis; Unicompartmental Knee Arthroscopy

Summary: this study will be conducted to assess the survivorship of a particular prosthesis used in unicompartmental knee arthroplasties. patients undergoing this procedure have been diagnosed with isolated medial or lateral compartmental arthritis and have failed conservative treatment. the patients received a unicompartmental knee replacement using the sigma® hp partial knee system.

this study is an epidemiological level iv-case series clinical study that will study the survivorship of the sigma® hp partial knee system in a consecutive series of patients. all patients who received the sigma® hp partial knee system between august 21, 2008 and october 31, 2009 will be available to include in the study. data will be collected preoperatively, intra-operatively, and post-operatively at intervals of 6 weeks, 6 months, 1 year, 2 years, and 5 years. data will be analyzed for survivorship status at the 2- and 5-year follow-up visits. other data, including functional outcomes, radiographic outcomes, and wear will be analyzed at the 5-year follow-up visit. subjects will participate in the study for five years after their surgery.

Eligibility criteria:
inclusion criteria: * adult patient over the age of 18 * diagnosis of isolated medial or lateral compartmental osteoarthritis of the knee joint * must have failed conservative treatment and received a unicompartmental knee arthroplasty between august 21, 2008 and october 31, 2009. * must have received the sigma® hp partial knee system. * must have received the surgery from dr. almand, dr. johnson, or dr. pickering at mississippi sports medicine and orthopaedic center. * must be willing to provide written consent to participate in the study. * subjects who do not have the legal capacity to consent may be enrolled in the study by a legally authorized representative (lar). the lar must provide verification that they have the legal authority to represent the subject. exclusion criteria: * did not receive a unicompartmental knee arthroplasty between august 21, 2008 and october 31, 2009. * did not receive a unicompartmental knee arthroplasty using the sigma® hp partial knee. * did not receive their unicompartmental knee replacement from dr. almand, dr. johnson, or dr. pickering at mississippi sports medicine and orthopaedic center. * subjects lost to follow-up for any reason including, but not limited to: refusal to consent, death, or geographic isolation will also be excluded from the study.

Keywords: osteoarthritis knee replacement unicompartmental depuy sigma hp
study comparing test to aczone 7.5% and both to a placebo control in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: to evaluate the therapeutic effect of dpsg and placebo gel in the treatment of acne vulgaris.

a multi-center, double-blind, randomized, placebo controlled, parallel-group study comparing dpsg to aczone gel and active treatment to a placebo control in the treatment of acne vulgaris.

Eligibility criteria:
inclusion criteria: * healthy male or non pregnant female aged ≥ 12 years with a clinical diagnosis of acne vulgaris. exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation
multifactorial intervention on frailty in vulnerable older adults

Conditions: Frailty

Summary: frailty is a highly prevalent, progressive condition in older adults that is characterized by multisystem physiologic impairments and vulnerability to stressful events, leading to increased risk of geriatric conditions, disability, falls, hospitalization, and mortality. an effective public health intervention to improve frailty in a rural aging population with limited resources remains unknown. the purpose of our study is to evaluate the effectiveness of multidimensional public health intervention to reduce frailty and related geriatric conditions in older adults in rural communities. our hypotheses are that a multidimensional intervention consisting of group exercise, nutritional support, depression management, polypharmacy, and home safety intervention over a 6-month period will improve frailty and selected geriatric conditions in older adults who are in low socioeconomic status or living alone in a rural community. our primary outcome is short physical performance battery at 6 month. secondary outcomes include frailty status, nutritional status, depression, falls, sarcopenia, and health care utilization. the investigators will conduct a designed delay trial by implementing our intervention in one town for the first 6 months (intervention group), while measuring the outcomes without any intervention in another town (serving as a control group); in the following 6 months, the investigators will implement the 6-month intervention in the control town. the findings from our study will inform us to find effective public health interventions to promote healthy aging in resource-limited, rural populations.


Eligibility criteria:
inclusion criteria: 1. currently living in the pyeongchang county, gangwon province, south korea 2. aged 65 years or older 3. living alone or receiving medical aid services 4. sign informed consent exclusion criteria: 1. unable to walk 100 meters, with or without assistive devices 2. institutionalized for the past 6 months 3. known metastatic cancer, end-stage heart disease, end-stage renal disease 4. moderate to severe cognitive impairment (mmse ≤ 18) 5. plan to move out of the current residence in the next 6 months

Keywords: aspra cohort multifactorial intervention medicaid services geriatric disorder short physical performance battery
an open label exploratory study in newly diagnosed prostate cancer patients

Conditions: Prostatic Neoplasms

Summary: open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks) before prostatectomy


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of adenocarcinoma of the prostate gland via a minimum of 6 core biopsy samples. * subjects must be a candidate for radical prostatectomy * no evidence of metastatic disease as determined by ct scans and bone scans * more criteria apply exclusion criteria: * subjects from whom sufficient diagnostic biopsy material is not available for full characterization of the tumor * active infection requiring antibiotic therapy, or serious intercurrent illness, active bleeding, or ongoing urinary tract infection necessitating rapid or emergent surgical resection * subjects who have had hormonal injection or implants which will last longer than 6 months * more criteria apply
the prevalence of oral manifestation in patients with sars-cov2 infection

Conditions: SARS-CoV2 Infection

Summary: the sars-cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. current research showed that sars-cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ace2) through scrna-seq data analyses. the study identified the organs that are at risk and are vulnerable to sars-cov-2 infection. therefore, cells with ace2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. these results suggest that oral mucosa could be a target of sars-cov-2 infection

the oral cavity is particularly susceptible to viral infection with several viruses such as herpes simplex virus, cytomegalovirus and zika virus because of its structures, especially salivary glands and soft tissues . moreover, oral mucosa can be affected by secondary pathological process of a bacterial or fungal nature due to viral immunosuppression. the oral cavity could be considered a "biological barometer" of both viral infection and viral immunosuppression advancement . the sars-cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. current research showed that sars-cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ace2) through scrna-seq data analyses. the study identified the organs that are at risk and are vulnerable to sars-cov-2 infection. therefore, cells with ace2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. these results suggest that oral mucosa could be a target of sars-cov-2 infection . although many authors reported the presence of oral lesion associated with sars-cov2 infection, the prevalence of the oral manifestation and the range of oral manifestation are still unknown. further studies are necessary to better understanding of the symptoms of the sars-cov2 virus in order to faster detection. a multidisciplinary team following the patients could be the key in treatment of the infection and faster recovery.

Eligibility criteria:
inclusion criteria: * a diagnosis of sars-cov2 with pcr. * age range from 18-60 years old * hospital admission not more than 10 days exclusion criteria: * pregnancy or contraceptive pills * lactation * any auto-immune disease that could affect the oral mucosa * on any neoplastic therapy. * uncontrolled diabetes.

Keywords: sars-cov2 oral manifestation prevalence
the effect of mcgrath video laryngoscope on the glottic view at thyroid surgery position

Conditions: Thyroid Surgery

Summary: for thyroid surgery, the special body position (thyroid surgical position) to exposure the patient's neck should be needed. for intraoperative neuromonitoring (ionm) in thyroid surgery, the tube should be placed at a specific position. a video laryngoscope can have advantages in tracheal intubation on thyroid surgical position for thyroid surgery. the purpose of the study is to investigate the effect of mcgrath video laryngoscope on the glottic view when tracheal intubation is performed at the thyroid surgical position.

for thyroid surgery, the special body position (thyroid surgical position) to exposure the patient's neck should be needed. meanwhile, the tracheal tube can be moved in the trachea from the supine position to thyroid surgical position if tracheal intubation is performed at the supine position. for intraoperative neuromonitoring (ionm) in thyroid surgery, the electrode of the tracheal tube must be placed at a specific position, that is between the vocal cords. to perform initially tracheal intubation on the thyroid surgical position, therefore, can have advantage in terms of stability of tube position in the trachea without displacement by body position change. however, tracheal intubation on thyroid surgical position might be hard in terms of obtaining a good glottic view. it is well known that video laryngoscopes can improve the glottic view. therefore, a video laryngoscope can have advantages in tracheal intubation on thyroid surgical position for thyroid surgery in obtaining the good glottic view as well as minimal displacement of the tracheal tube because there is no need to change the patient's position. the purpose of the study is to investigate the effect of mcgrath video laryngoscope on the glottic view when tracheal intubation is performed at the thyroid surgical position.

Eligibility criteria:
inclusion criteria: * patients schedule to thyroid surgery exclusion criteria: * disagree to participate * patients with weak teeth
fct with young children with id in the uk: a feasibility project v.1

Conditions: Intellectual Disability

Summary: the current project aims to assess the feasibility of conducting functional communication training in the uk with a small sample of young children (aged under 9) in an nhs setting. three delivery formats will be assessed in order to demonstrate the feasibility of conducting fct via different delivery methods within an nhs context. participants will be four children aged under 9 who have an identified intellectual / developmental disability and display either self-injury, property destruction, or aggression at home. in addition, one family carer per child will be coached to implement the intervention, either following researcher intervention, or from the beginning. data will be collected on challenging behaviour, communication responses, family carer confidence in managing behaviour, fidelity of intervention implementation, family quality of life, and acceptability of the intervention.


Eligibility criteria:
inclusion criteria: * child aged under 9 * child has identified intellectual disability or genetic syndrome associated with intellectual disability (e.g. fragile x syndrome) * child uses only phrase speech (i.e. 2-3 word utterances) * child displays self injury, aggression, property destruction at home * family carers aged over 18 with capacity to consent * family carer speaks english as first language (to ensure that the child understands english and will therefore understand researcher) exclusion criteria: * child experiences health condition involving pain that is not well controlled by treatment * child is fully deaf / blind * child or family carer receiving active treatment in relation to child's behaviour (e.g. direct behavioural support, parenting programme etc.)

Keywords: challenging behaviour functional communication training positive behavioural support family carer training
ucsf bp activate letter study

Conditions: Hypertension

Summary: the bp activate study aims to assess the effectiveness of the bp report letter with personalized bp medication recommendations, compared with control letters and no intervention, at shortening time to appointment, time to visit, time to medication change, and time to achievement of bp goal.

the bp activate study is a randomized quality improvement trial. we will deliver one of two versions of a letter to established english-speaking primary care patients at mt zion with uncontrolled hypertension, defined by sbp\>140 or dbp\>90 in the past two years (identified via ehr). the letter will prompt patients to schedule a visit with their provider or team nurse practitioner to discuss their bp recommendations with their clinician. we will test 2 versions of the letter and a usual care control: 1. the "bp activate report letter" group will get a letter that presents recommendations for medication changes from a computerized algorithm using the patient's medical records and recommends discussing these specific recommendations with their clinician; or 2. the "control letter" group will get a letter that suggests they talk to their clinician about their bp without providing any specific medication recommendations. 3. the "usual care" group will not receive any intervention. this primary goal of the study is to assess the effectiveness of the bp activate report letter compared with the control letter, and see if it shortens time to appointment, time to visit, time to medication change (primary outcome), and time to achievement of bp goal. clinicians, with patient input, will still have full control of how bp is clinically managed. a small number of patients will be contacted by a research coordinator to hear what they thought when they received the letter, and why they did or did not act upon the information.

Eligibility criteria:
inclusion criteria: * patient is a primary care patient of a clinician in a general internal medicine clinic who has agreed to have their patients participate in the study * lowest sbp\>140 or lowest dbp\>90 at last visit in general internal medicine clinic * last visit in general internal medicine clinic was \< 2 years ago * engagerx algorithm determines that a medication intensification step is indicated exclusion criteria: * primary language is not english * patient's provider indicates (through an active opt-out process) that they do not want the patient to receive a bp activate letter
probiotic supplements in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: this research will investigate the effect of oral probiotic supplements on renal function, uremic toxins inflammatory response, nutrition status, gastrointestinal symptoms, and qol with chronic kidney disease.

chronic kidney disease (ckd) with gut microbiota was different from a normal person. some gut microbiota produces short-chain fatty acids or induces functional enzymes beneficial to patients. on the other hand, some gut microbiota may also metabolize amino acids into p-cresol and indole which were leading to the accumulation of urinary toxins and damage to the kidney. this research will investigate the effect of oral probiotic supplements on renal function, uremic toxins, inflammatory response, nutrition status, gastrointestinal symptoms, and qol with ckd.

Eligibility criteria:
inclusion criteria: 1. aged over 20 years old. 2. patients with 2\~3a stage chronic kidney disease. 3. those who can cooperate with the research plan for 3 visits and retain samples (blood, urine). exclusion criteria:: 1. use of other probiotics during the study. 2. those with active infectious diseases in the past month. 3. those who have used antibiotics within the past 1 month or during the study. 4. women who are pregnant or breastfeeding. 5. obstructive nephropathy within the past month. 6. polycystic kidney disease (polycystic kidney disease). 7. acute kidney disease within the past 3 months. 8. gastrointestinal bleeding within the past 3 months. 9. malignancy. 10. severe cardiovascular disease (cardiovascular disease) in the past 3 months, such as coronary artery disease (coronary artery disease), myocardial ischemia (myocardial ischemia), nyha class iv myocardial failure, cerebrovascular disease, or peripheral artery disease.

Keywords: probiotics chronic kidney disease
evaluation of antigen-specific t cells in patients with antisynthetase syndrome and interstitial lung disease

Conditions: Antisynthetase Syndrome

Summary: antisynthetase syndrome (as) is a rare overlapping myositis characterized by cellular and humoral autoimmune responses directed against aminoacyl-trna synthetases. intesrtitial lung disease (ild) is a leading cause of mortality in antisynthetase syndrome. recently, antigen-specific ifn-γ+ cd4+ t cells have been identified in bronchoalveolar fluid (bal) of patients with antisynthetase syndrome and ild. elevated levels of il1β, il12, il18, tnfα, il17a, il22 have also been detected in peripheral blood of as patients, especially those with progressive ild. implication of innate lymphoid cells (ilc) and mucosal-associated invariant t cells (mait) have not yet been studied in patients with as. targeted therapies against th1 and th17 cells may represent a promising treatment in patients as patients with ild. investigators suppose that antigen-specific th1 and th17 cells, ilc and mait at ild diagnosis are associated with ild severity at diagnosis and could predict treatment response at 6 months. the main objective is to study the correlation between bal antigen-specific th1 and th17 cells at ild diagnosis and clinical evolution after 6 months of treatment according to initial ild severity.


Eligibility criteria:
inclusion criteria: * patient with new diagnosis of as with ild exclusion criteria: * patient with ild differential diagnosis * corticosteroid treatment, immunosuppresive or immunomodulatory drugs in the past 3 months before diagnosis
oral contraceptive and cardiovascular risk in pcos

Conditions: Polycystic Ovary Syndrome

Summary: oral contraceptive therapy is routinely used for the treatment of menstrual disturbances of patients with polycystic ovary syndrome (pcos). to date, the cardiovascular risk (cvr) of the oral contraceptives (oc) are known but no data are available on the cvr in pcos patients treated with oc or physical exercise. the purpose of this study is to compare the effects of oc to physical exercise on the cvr of pcos women and show the hormonal and metabolic effects of these two different treatment. we hypothesize that physical exercise has the same beneficial effects of oc therapy on hormonal and metabolic features of pcos women with less cardiovascular consequences.

one hundred and fifty pcos women will be enrolled. the diagnosis of pcos was made based according to the rotterdam criteria (1). specifically, patients with anovulation and clinical and/or biochemical hyperandrogenism were enrolled. patients will be randomly allocated in three groups (oc, physical exercise and placebo group) using a computer-software. fifty pcos patients will be treated with oc (drospirenone 3 mg, ethynylestradiol 30 microgram = yasmin, schering, milan,italy) other fifty pcos will be undergone physical exercise, whereas other fifty will be treated with placebo tablets (one tablet once daily; placebo group). the duration of the treatment will be 6 months. patients treated with oc will be instructed to follow their usual diet and physical activity, whereas patients undergone to physical exercise will be instructed to follow a detailed regular physical training program and for the diet they will be advised for the quality of food to eat. all subjects will be nonsmokers and none will drink alcoholic beverages. each subject will undergo follow-up visits under (at three and 6 months from treatment starting) and after treatment (at three and 6 months from treatment withdrawal). at each follow-up visit, in all subjects the same operator will perform clinical, hormonal, metabolic and cardiovascular assessments by carotid and brachial artery us

Eligibility criteria:
inclusion criteria: * polycystic ovary syndrome exclusion criteria: * age \ 40 years * bmi higher than 30 and lower than 18 * pregnancy * hypothyroidism, hyperprolactinemia, cushing's syndrome, nonclassical congenital adrenal hyperplasia, use of oc, glucocorticoids, antiandrogens, ovulation induction agents, antidiabetic or antiobesity drugs or other hormonal drugs within the previous 6 months * subjects with neoplastic, metabolic (including glucose intolerance), hepatic, and cardiovascular disorder or other concurrent medical illness (i.e. diabetes, renal disease, or malabsorptive disorders, cephalea)

Keywords: pcos oral contraceptives physical exercise cvr
comparison of the effectiveness of therapeutic ultrasound and phonophoresis in chronic low back pain

Conditions: Low Back Pain

Summary: the aim of this study is to evaluate the effects of therapeutic ultrasound and phonophoresis applications on pain, range of motion, flexibility and functional capacity in patients with chronic low back pain. the study is planned as the first scientific study comparing the effectiveness of these two physiotherapy methods in the treatment of chronic low back pain. it is aimed to make national and international publications with the data obtained at the end of the study. the study will be conducted in a randomised single-blind, placebo-controlled design. 60 patients aged 18-30 years with chronic low back pain will be divided into 3 groups: therapeutic ultrasound (us) application, phonophoresis application and placebo us group. in addition to ultrasound and phonophoresis, tens, infrared and low back exercises will be applied to all groups as treatment. pain intensity (vas), functional status (oswestry disability index), flexibility (sit-to-sit test) and range of motion (goniometric measurements) will be assessed throughout the treatment period. the study aims to make an important contribution from a clinical and economic point of view, given the increasing prevalence of low back pain worldwide and the need for treatment. the findings may guide the development of future treatment modalities.


Eligibility criteria:
inclusion criteria: individuals with low back pain for more than 3 months and pain intensity more than 5 according to vas will be included in the study exclusion criteria: patients who have undergone surgical operations